Trial Profile
A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Registrational
- Sponsors Titan Pharmaceuticals
- 22 Oct 2019 According to a Titan Pharmaceuticals media release, results from analysis of data from PRO-805, PRO-806, PRO-807, PRO-810 and PRO-811 Phase 3 clinical studies will be presented at the 10th American Conference on Pharmacometrics.
- 05 Mar 2014 New trial record